Long-term outcomes of multimodality management for parasagittal meningiomas

Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2020-04, Vol.147 (2), p.441-450
Hauptverfasser: Hua, Lingyang, Wang, Daijun, Zhu, Hongda, Deng, Jiaojiao, Luan, Shihai, Chen, Haixia, Sun, Shuchen, Tang, Hailiang, Xie, Qing, Wakimoto, Hiroaki, Gong, Ye
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 450
container_issue 2
container_start_page 441
container_title Journal of neuro-oncology
container_volume 147
creator Hua, Lingyang
Wang, Daijun
Zhu, Hongda
Deng, Jiaojiao
Luan, Shihai
Chen, Haixia
Sun, Shuchen
Tang, Hailiang
Xie, Qing
Wakimoto, Hiroaki
Gong, Ye
description Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. Results A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). Conclusions This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.
doi_str_mv 10.1007/s11060-020-03440-9
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2363087830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2363087830</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMo7rr6BzxIwYuX6qRJk_Yoi1-44EXBW0jTtHRpmjVJD_vvzdpVwYOHMJB55p3hQegcwzUG4DceY2CQQhYfoRTS8gDNcc5Jygknh2gOmPE0L-n7DJ14vwYAygk-RjOSQVEUmM7R88oObRq0M4kdg7JG-8Q2iRn70Blby74L28TIQbba6CEkjXXJRjrpZduFIPsk_nZD21kj_Sk6amTv9dm-LtDb_d3r8jFdvTw8LW9XqSI8D2nVgMSszJnCpcJ5zRUmUFclkxTzqpKMZxnNcgKkUFVFqM5k1dScx15RN6okC3Q15W6c_Ri1D8J0Xum-l4O2oxcZYQQKXsSEBbr8g67t6IZ4XaQKxqIOxiKVTZRy1nunG7FxnZFuKzCInWoxqRZRtfhSLXZXXOyjx8ro-mfk220EyAT42Bpa7X53_xP7CY63iZ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2386673166</pqid></control><display><type>article</type><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</creator><creatorcontrib>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</creatorcontrib><description>Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. Results A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). Conclusions This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-020-03440-9</identifier><identifier>PMID: 32088814</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Brain cancer ; Clinical Study ; Combined Modality Therapy ; Disease Management ; Female ; Follow-Up Studies ; Humans ; Male ; Medicine ; Medicine &amp; Public Health ; Meningeal Neoplasms - mortality ; Meningeal Neoplasms - pathology ; Meningeal Neoplasms - therapy ; Meningioma ; Meningioma - mortality ; Meningioma - pathology ; Meningioma - therapy ; Middle Aged ; Neurology ; Oncology ; Patients ; Prognosis ; Radiation therapy ; Retrospective Studies ; Survival Rate ; Tumors ; Young Adult</subject><ispartof>Journal of neuro-oncology, 2020-04, Vol.147 (2), p.441-450</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2020.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</citedby><cites>FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</cites><orcidid>0000-0001-5647-3008</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11060-020-03440-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11060-020-03440-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32088814$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hua, Lingyang</creatorcontrib><creatorcontrib>Wang, Daijun</creatorcontrib><creatorcontrib>Zhu, Hongda</creatorcontrib><creatorcontrib>Deng, Jiaojiao</creatorcontrib><creatorcontrib>Luan, Shihai</creatorcontrib><creatorcontrib>Chen, Haixia</creatorcontrib><creatorcontrib>Sun, Shuchen</creatorcontrib><creatorcontrib>Tang, Hailiang</creatorcontrib><creatorcontrib>Xie, Qing</creatorcontrib><creatorcontrib>Wakimoto, Hiroaki</creatorcontrib><creatorcontrib>Gong, Ye</creatorcontrib><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. Results A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). Conclusions This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain cancer</subject><subject>Clinical Study</subject><subject>Combined Modality Therapy</subject><subject>Disease Management</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Meningeal Neoplasms - mortality</subject><subject>Meningeal Neoplasms - pathology</subject><subject>Meningeal Neoplasms - therapy</subject><subject>Meningioma</subject><subject>Meningioma - mortality</subject><subject>Meningioma - pathology</subject><subject>Meningioma - therapy</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Retrospective Studies</subject><subject>Survival Rate</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kE1LxDAQhoMo7rr6BzxIwYuX6qRJk_Yoi1-44EXBW0jTtHRpmjVJD_vvzdpVwYOHMJB55p3hQegcwzUG4DceY2CQQhYfoRTS8gDNcc5Jygknh2gOmPE0L-n7DJ14vwYAygk-RjOSQVEUmM7R88oObRq0M4kdg7JG-8Q2iRn70Blby74L28TIQbba6CEkjXXJRjrpZduFIPsk_nZD21kj_Sk6amTv9dm-LtDb_d3r8jFdvTw8LW9XqSI8D2nVgMSszJnCpcJ5zRUmUFclkxTzqpKMZxnNcgKkUFVFqM5k1dScx15RN6okC3Q15W6c_Ri1D8J0Xum-l4O2oxcZYQQKXsSEBbr8g67t6IZ4XaQKxqIOxiKVTZRy1nunG7FxnZFuKzCInWoxqRZRtfhSLXZXXOyjx8ro-mfk220EyAT42Bpa7X53_xP7CY63iZ0</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Hua, Lingyang</creator><creator>Wang, Daijun</creator><creator>Zhu, Hongda</creator><creator>Deng, Jiaojiao</creator><creator>Luan, Shihai</creator><creator>Chen, Haixia</creator><creator>Sun, Shuchen</creator><creator>Tang, Hailiang</creator><creator>Xie, Qing</creator><creator>Wakimoto, Hiroaki</creator><creator>Gong, Ye</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5647-3008</orcidid></search><sort><creationdate>20200401</creationdate><title>Long-term outcomes of multimodality management for parasagittal meningiomas</title><author>Hua, Lingyang ; Wang, Daijun ; Zhu, Hongda ; Deng, Jiaojiao ; Luan, Shihai ; Chen, Haixia ; Sun, Shuchen ; Tang, Hailiang ; Xie, Qing ; Wakimoto, Hiroaki ; Gong, Ye</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bf0a16956c19c15d7c130db96a417bba67224253038cbb34e2abfd777bb8dfc93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain cancer</topic><topic>Clinical Study</topic><topic>Combined Modality Therapy</topic><topic>Disease Management</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Meningeal Neoplasms - mortality</topic><topic>Meningeal Neoplasms - pathology</topic><topic>Meningeal Neoplasms - therapy</topic><topic>Meningioma</topic><topic>Meningioma - mortality</topic><topic>Meningioma - pathology</topic><topic>Meningioma - therapy</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Retrospective Studies</topic><topic>Survival Rate</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hua, Lingyang</creatorcontrib><creatorcontrib>Wang, Daijun</creatorcontrib><creatorcontrib>Zhu, Hongda</creatorcontrib><creatorcontrib>Deng, Jiaojiao</creatorcontrib><creatorcontrib>Luan, Shihai</creatorcontrib><creatorcontrib>Chen, Haixia</creatorcontrib><creatorcontrib>Sun, Shuchen</creatorcontrib><creatorcontrib>Tang, Hailiang</creatorcontrib><creatorcontrib>Xie, Qing</creatorcontrib><creatorcontrib>Wakimoto, Hiroaki</creatorcontrib><creatorcontrib>Gong, Ye</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hua, Lingyang</au><au>Wang, Daijun</au><au>Zhu, Hongda</au><au>Deng, Jiaojiao</au><au>Luan, Shihai</au><au>Chen, Haixia</au><au>Sun, Shuchen</au><au>Tang, Hailiang</au><au>Xie, Qing</au><au>Wakimoto, Hiroaki</au><au>Gong, Ye</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term outcomes of multimodality management for parasagittal meningiomas</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>147</volume><issue>2</issue><spage>441</spage><epage>450</epage><pages>441-450</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose The aim of this study was to systematically analyze the clinical characteristics of a large cohort of parasagittal meningioma (PM) and to evaluate the patients’ outcomes and best treatment strategies based on tumor features. Methods To minimize selection bias we performed a single-institutional review of PM with restricted criteria. One hundred and ninety-two consecutive patients who met criteria for inclusion were reviewed from 2003 to 2011 in our general hospital. Results A total of 131 cases (68.2%) were with WHO grade I, while grade II and grade III PMs constituted 40 (20.8%) and 21 cases (10.9%). Higher histological grade was associated with loss of trimethylation of H3K27 (P = 0.000). For WHO grade I PMs, GTR was significantly associated with a better PFS (P = 0.023); however, adjuvant radiotherapy did not benefit patients with STR (P = 0.215). For de novo high-grade (WHO grade II and III) PMs (n = 37), adjuvant radiotherapy was associated with a significantly longer OS (P = 0.013), while no difference was observed between GTR and STR (P = 0.654). In recurrent high-grade PM patients (n = 24), GTR combined with adjuvant radiotherapy increased PFS (P = 0.005). Conclusions This study demonstrated that PMs were a heterogeneous group of tumors with a high proportion of high-grade tumors that often displayed aggressive clinical behaviors. Low-grade PM benefited from radical resection, whereas high-grade de novo PM did not. Adjuvant radiotherapy significantly prolonged OS for high-grade primary PM, but did not impact survival of patients with subtotally resected low-grade tumors. Long-term outcome of high-grade recurrent PMs was dismal. We thus show that extent of tumor resection, tumor grade and tumor recurrent status inform therapeutic decisions for PMs.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>32088814</pmid><doi>10.1007/s11060-020-03440-9</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-5647-3008</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0167-594X
ispartof Journal of neuro-oncology, 2020-04, Vol.147 (2), p.441-450
issn 0167-594X
1573-7373
language eng
recordid cdi_proquest_miscellaneous_2363087830
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adolescent
Adult
Aged
Aged, 80 and over
Brain cancer
Clinical Study
Combined Modality Therapy
Disease Management
Female
Follow-Up Studies
Humans
Male
Medicine
Medicine & Public Health
Meningeal Neoplasms - mortality
Meningeal Neoplasms - pathology
Meningeal Neoplasms - therapy
Meningioma
Meningioma - mortality
Meningioma - pathology
Meningioma - therapy
Middle Aged
Neurology
Oncology
Patients
Prognosis
Radiation therapy
Retrospective Studies
Survival Rate
Tumors
Young Adult
title Long-term outcomes of multimodality management for parasagittal meningiomas
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T15%3A08%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20outcomes%20of%20multimodality%20management%20for%20parasagittal%20meningiomas&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Hua,%20Lingyang&rft.date=2020-04-01&rft.volume=147&rft.issue=2&rft.spage=441&rft.epage=450&rft.pages=441-450&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-020-03440-9&rft_dat=%3Cproquest_cross%3E2363087830%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2386673166&rft_id=info:pmid/32088814&rfr_iscdi=true